However, heterogeneity was observed for annualized rates of anytime (24 hours) or nocturnal (00:00-05:59 hours) confirmed hypoglycaemia (в‰¤70 mg/dL ) over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the в‰Ґ90 mL/min/1.73 m 2. HbA1c reductions were similar between treatments in the other eGFR subgroups.

02), reflecting a greater mean glycated haemoglobin (HbA1c) reduction from baseline to week 24 with Gla-300 versus IDeg-100 in the eGFR <60 mL/min/1.73 m 2 subgroup (least squares mean difference: -0.43% ), while there were no differences in hypoglycaemia incidence or rates over 24 weeks in that subgroup. Heterogeneity of treatment effect across renal function subgroups was observed (P =. Participants were randomized 1:1 to evening Gla-300 (n = 466) or IDeg-100 (n = 463) and stratified based on baseline estimated glomerular filtration rate (eGFR) for this analysis. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) are affected by renal function in a prespecified subgroup analysis from the BRIGHT trial.Д«RIGHT ( NCT02738151) was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in insulin-naГЇve uncontrolled type 2 diabetes (T2D). Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality.

Que es ctrl u